PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast - David R. Jones, MD - Adjuvant EGFR-Targeted Therapy as a Game Changer: How to Implement New Standards of Care in Multimodal Management of Stage I-III EGFR-Mutated NSCLC

David R. Jones, MD - Adjuvant EGFR-Targeted Therapy as a Game Changer: How to Implement New Standards of Care in Multimodal Management of Stage I-III EGFR-Mutated NSCLC

12/20/21 • 61 min

PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast

Go online to PeerView.com/MHD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. How have the best practices for multidisciplinary management of patients with stage I-III lung cancer changed now that adjuvant EGFR-targeted therapy has become the new standard of care in resected early-stage EGFR-mutated NSCLC, and what are the implications for thoracic surgeons and other key members of the lung cancer care team? This PeerView Live Candid Conversations & Clinical Consults, based on a recent web broadcast, answers these and other burning questions. Experts in thoracic surgery and medical oncology come together to discuss recent advances, as well as provide practical, case-based guidance on the importance of biomarker testing in early-stage settings. In addition, they provide direction on how to determine which patients are appropriate candidates for adjuvant EGFR-targeted therapy, if adjuvant chemotherapy is still needed, which considerations should be discussed with patients, and how thoracic surgeons, medical oncologists, pathologists, and other relevant specialists can effectively work together to determine the best multimodal treatment approach for each patient with stage I-III NSCLC. Upon completion of this CE activity, participants will be able to: Discuss the role of EGFR mutations in NSCLC, the importance of identifying patients with EGFR mutations in earlier disease settings, and the role of thoracic surgeons in biomarker testing and treatment selection in the era of precision oncology, Optimize sample collection and EGFR testing in early-stage NSCLC to identify patients with EGFR mutations who might benefit from EGFR-targeted therapy, Apply the latest evidence and guidelines on EGFR-targeted therapies to select optimal therapy for patients with early-stage EGFR-mutated NSCLC, Implement multidisciplinary strategies and shared decision-making to optimize biomarker testing and safely integrate adjuvant EGFR-targeted therapy into multimodal treatment plans for eligible patients with early-stage NSCLC in clinical practice or through clinical trial enrollment.

Previous Episode

undefined - Stephen V. Liu, MD / Bhavesh Shah, RPh, BCOP - Immunotherapy in the Treatment Arsenal for Small Cell Lung Cancer, and Managed Care Implications for the "Four Ps": Patient, Provider, Pharmacy, and Plan

Stephen V. Liu, MD / Bhavesh Shah, RPh, BCOP - Immunotherapy in the Treatment Arsenal for Small Cell Lung Cancer, and Managed Care Implications for the "Four Ps": Patient, Provider, Pharmacy, and Plan

Go online to PeerView.com/TMR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in oncology and managed care provide a foundational overview of the mechanism of action of cancer immunotherapies and why this class of agents is different from other oncologic therapies. The panel also explores how immunotherapies have revolutionized the management of cancer over the last few years, particularly the ways in which SCLC management is finally changing. Additionally, the latest research and practical considerations for value assessment of cancer immunotherapies in managed care settings are presented, with specific implications for SCLC. Upon completion of this activity, participants will be able to: Describe the rationale for and potential benefits of integrating immunotherapies and immune-based combination approaches into the SCLC treatment arsenal throughout the disease continuum, Review efficacy and safety findings from key clinical trials assessing immunotherapies and combination approaches across different treatment settings of SCLC, as well as data on potential biomarkers, Incorporate immunotherapies into treatment plans for appropriate patients with SCLC in managed care settings.

Next Episode

David F. McDermott, MD - How I Think, How I Treat: Individualizing RCC Therapy in the Era of Immuno-Oncology

Go online to PeerView.com/TKZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. With new developments in the advanced renal cell carcinoma (RCC) treatment landscape, clinicians have more opportunities for personalizing therapeutic approaches for patients with RCC. Validation of novel combinatorial approaches, such as dual checkpoint inhibition and immunotherapy plus targeted agents, have led to FDA approvals, and novel approaches synergistically combining checkpoint inhibition with targeted therapy have expanded frontline treatment options for patients with advanced disease. This program features the latest research on the efficacy and safety of these newer treatment approaches and expert guidance on selecting and managing the overlapping and non-overlapping adverse events associated with potent immune-based and targeted therapy treatment options. Upon completion of this activity, participants sould be better able to: Identify the latest efficacy and safety findings on new treatment approaches, such as immune checkpoint inhibitors, targeted tyrosine kinase inhibitors, and novel and emerging combination approaches, for advanced and/or resectable renal cell carcinoma (RCC), Choose appropriate, personalized treatment regimens that make use of immune and targeted therapies for patients with advanced RCC in the first-line setting based on pertinent patient- and disease-related characteristics, Integrate novel components into treatment plans over multiple lines of therapy for patients with previously-treated advanced RCC taking into account patient treatment history and comorbidities, Assess treatment-related adverse events in patients with RCC receiving immunotherapy and targeted agents.